Table II.

Test Agsa

AgDescription/SourceDerivation, Comments
PILilly Pharm.E. coli, full-length*
IA-2Bayer Pharm.E. coli, “ICA512”*
GAD65Peptide 524SRLSKVAPVIKARMMEYGTT*
HSP60Peptide 277VLGGGCALLRCIPALDSLTPANED*
ICA69β-isoformE. coli*
α-isoformBaculovirus
ICA69-36 “Tep69”AFIKATGKKEDE, homolog BSA-148*
ICA69-202KNFDKLKMDVCQ, homolog BSA-394
ICA69-350SEEGACLGPVAG, homolog BSA-193
BSASigmaFraction V*
BSA-148 “ABBOS”FKADEKKFWGKYL, homolog ICA69-36*
BSA-394TSVFDKLKHLVD, homolog ICA69-202
BSA-193EDKGACLLPKIE, homolog ICA69-350
Tetanus toxoidPMC CanadaPharmaceutical grade*
OVASigmaFraction V*
OVA152EYQDNRVSFLGHFI*
Human hemoglob.SigmaPurified
Human cytochr. cSigmaPurified
Human actinSigmaPurified
  • a Description of the test antigens/peptides used, not all could be tested in all study subjects. Eleven Ags (marked with an asterisk) were used routinely; the remainder (marked with a dagger) were tested only in subsets of probands to answer specific questions. Peptide names indicate origin and N-terminal amino acid position. Residues printed in bold identify homologies described in the text.